IRIS Accounts Production v26.1.10.60 11029379 director 1.11.24 31.10.25 31.10.25 false true false false true false Ordinary 1.00000 Ordinary B 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh110293792024-10-31110293792025-10-31110293792024-11-012025-10-31110293792023-10-31110293792023-11-012024-10-31110293792024-10-3111029379ns15:EnglandWales2024-11-012025-10-3111029379ns14:PoundSterling2024-11-012025-10-3111029379ns10:Director12024-11-012025-10-3111029379ns10:PrivateLimitedCompanyLtd2024-11-012025-10-3111029379ns10:SmallEntities2024-11-012025-10-3111029379ns10:AuditExempt-NoAccountantsReport2024-11-012025-10-3111029379ns10:SmallCompaniesRegimeForDirectorsReport2024-11-012025-10-3111029379ns10:SmallCompaniesRegimeForAccounts2024-11-012025-10-3111029379ns10:FullAccounts2024-11-012025-10-3111029379ns10:OrdinaryShareClass12024-11-012025-10-3111029379ns10:OrdinaryShareClass22024-11-012025-10-3111029379ns10:RegisteredOffice2024-11-012025-10-3111029379ns5:CurrentFinancialInstruments2025-10-3111029379ns5:CurrentFinancialInstruments2024-10-3111029379ns5:ShareCapital2025-10-3111029379ns5:ShareCapital2024-10-3111029379ns5:RetainedEarningsAccumulatedLosses2025-10-3111029379ns5:RetainedEarningsAccumulatedLosses2024-10-3111029379ns5:PlantMachinery2024-11-012025-10-3111029379ns5:PlantMachinery2024-10-3111029379ns5:ComputerEquipment2024-10-3111029379ns5:ComputerEquipment2024-11-012025-10-3111029379ns5:PlantMachinery2025-10-3111029379ns5:ComputerEquipment2025-10-3111029379ns5:PlantMachinery2024-10-3111029379ns5:ComputerEquipment2024-10-3111029379ns5:WithinOneYearns5:CurrentFinancialInstruments2025-10-3111029379ns5:WithinOneYearns5:CurrentFinancialInstruments2024-10-3111029379ns5:DeferredTaxation2024-10-3111029379ns5:DeferredTaxation2024-11-012025-10-3111029379ns5:DeferredTaxation2025-10-3111029379ns10:OrdinaryShareClass12025-10-3111029379ns10:OrdinaryShareClass22025-10-3111029379ns5:RetainedEarningsAccumulatedLosses2024-10-3111029379ns5:RetainedEarningsAccumulatedLosses2024-11-012025-10-31
REGISTERED NUMBER: 11029379 (England and Wales)















Unaudited Financial Statements for the Year Ended 31 October 2025

for

Bite Back Oncology Services Limited

Bite Back Oncology Services Limited (Registered number: 11029379)






Contents of the Financial Statements
for the Year Ended 31 October 2025




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Bite Back Oncology Services Limited

Company Information
for the Year Ended 31 October 2025







DIRECTOR: Dr R Elders





REGISTERED OFFICE: PO Box Unit 73
86 Bancroft
HITCHIN
SG5 1NQ





REGISTERED NUMBER: 11029379 (England and Wales)





ACCOUNTANTS: D and E Accountancy Ltd
Tax Advisors and Accountants
2nd Floor, 2 Walsworth Road
Hitchin
Hertfordshire
SG4 9SP

Bite Back Oncology Services Limited (Registered number: 11029379)

Balance Sheet
31 October 2025

31.10.25 31.10.24
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 2,368 3,071

CURRENT ASSETS
Debtors 5 1,436 1,303
Cash at bank 32 9
1,468 1,312
CREDITORS
Amounts falling due within one year 6 5,503 4,540
NET CURRENT LIABILITIES (4,035 ) (3,228 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

(1,667

)

(157

)

CAPITAL AND RESERVES
Called up share capital 8 2 2
Retained earnings 9 (1,669 ) (159 )
SHAREHOLDERS' FUNDS (1,667 ) (157 )

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 October 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 October 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Bite Back Oncology Services Limited (Registered number: 11029379)

Balance Sheet - continued
31 October 2025


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 3 July 2026 and were signed by:





Dr R Elders - Director


Bite Back Oncology Services Limited (Registered number: 11029379)

Notes to the Financial Statements
for the Year Ended 31 October 2025

1. STATUTORY INFORMATION

Bite Back Oncology Services Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery - 25% on reducing balance

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2024 - 1 ) .

Bite Back Oncology Services Limited (Registered number: 11029379)

Notes to the Financial Statements - continued
for the Year Ended 31 October 2025

4. TANGIBLE FIXED ASSETS
Plant and Computer
machinery equipment Totals
£    £    £   
COST
At 1 November 2024
and 31 October 2025 3,190 4,112 7,302
DEPRECIATION
At 1 November 2024 2,432 1,799 4,231
Charge for year 189 514 703
At 31 October 2025 2,621 2,313 4,934
NET BOOK VALUE
At 31 October 2025 569 1,799 2,368
At 31 October 2024 758 2,313 3,071

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.10.25 31.10.24
£    £   
Other debtors 1,436 1,303

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.10.25 31.10.24
£    £   
Directors' current accounts 5,203 3,940
Accrued expenses 300 600
5,503 4,540

7. DEFERRED TAX
£   
Balance at 1 November 2024 (1,303 )
Credit to Income Statement during year (133 )
Balance at 31 October 2025 (1,436 )

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 31.10.25 31.10.24
value: £    £   
1 Ordinary £1 1 1
1 Ordinary B £1 1 1
2 2

Bite Back Oncology Services Limited (Registered number: 11029379)

Notes to the Financial Statements - continued
for the Year Ended 31 October 2025

9. RESERVES
Retained
earnings
£   

At 1 November 2024 (159 )
Deficit for the year (1,510 )
At 31 October 2025 (1,669 )